

Clinical Trial Protocol

Iranian Registry of Clinical Trials

28 Sep 2026

Comparison of duloxetine and pregabalin Effects on invalidation score and depression in Patients with Fibromyalgia.

Protocol summary

Study aim

The goal of the study is comparison of duloxetine and pregabalin effects on invalidation score and depression in patients with fibromyalgia.

Design

open-label randomized clinical trial

Settings and conduct

This study will be conducted in subspecialty clinic of Razi hospital of Rasht under a rheumatology specialist. Diagnosis of patients is based on ACR 2010. All patients will complete and sign informed consent, then the patients will be randomized into two groups using random blocks of allocation. Patients will complete the inventories of illness invalidation, beck depression and FIQR in starting of the study and 1 month later. All data will be analyzed by special statistical softwares.

Participants/Inclusion and exclusion criteria

Inclusion criteria:female,patients must meet the American College of Rheumatology criteria for fibromyalgia(ACR2010) and rheumatologist confirm fibromyalgia diagnosis. Exclusion criteria:age younger than 18 or older than 65 years old, pregnancy or plans to become pregnant, taking MAOIs, chronic disease, history of sensitivity to Pregabalin and Duloxetine .

Intervention groups

Two groups of fibromyalgia patients: one group receive duloxetine capsules 30 mg daily initially, and finally 60 mg daily from Lilly's Pharmaceutical Company, and the other group receive pregabalin 75 mg initially and finally 150 mg daily from Pfizer company.

Main outcome variables

Invalidation in patient with fibromyalgia;Beck depression score in patient with fibromyalgia

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20181113041646N1**

Registration date: **2019-11-05, 1398/08/14**

Registration timing: **prospective**

Last update: **2019-11-05, 1398/08/14**

Update count: **0**

Registration date

2019-11-05, 1398/08/14

Registrant information

Name

Ashkan Rahimi

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 13 3467 2363

Email address

ashkan96shamami@gmail.com

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2019-11-21, 1398/08/30

Expected recruitment end date

2020-05-21, 1399/03/01

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Comparison of duloxetine and pregabalin Effects on invalidation score and depression in Patients with Fibromyalgia.

Public title

Effect of duloxetine and pregabalin on invalidation in fibromyalgia.

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria:

Female . Patients must meet the American College of Rheumatology criteria for fibromyalgia (ACR2010). A rheumatologist confirm diagnosis of fibromyalgia.

Exclusion criteria:

Age younger than 18 or older than 65 years old
Pregnancy . Taking MAOIs (monoamine oxidase inhibitors) in the 14 days before study. Cases of chronic liver disease, severe renal failure and uncontrolled narrow angle glaucoma. History of sensitivity to Pregabalin and its components. History of sensitivity to Duloxetine and its components.

Age

From **18 years** old to **65 years** old

Gender

Female

Phase

3

Groups that have been masked

No information

Sample size

Target sample size: **68**

Randomization (investigator's opinion)

Randomized

Randomization description

Randomized allocation with block method by statistical software .

Blinding (investigator's opinion)

Not blinded

Blinding description

Placebo

Not used

Assignment

Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Ethics committee of guilan university of medical sciences

Street address

Rasht,Namjoo avenue,shahid siadati street,infront of 17shahrivar hospital

City

Rasht

Province

Guilan

Postal code

4144895655

Approval date

2019-07-21, 1398/04/30

Ethics committee reference number

IR.GUMS.REC.1398.208

Health conditions studied

1

Description of health condition studied

Invalidation in patient with fibromyalgia

ICD-10 code

M79.7

ICD-10 code description

Fibromyalgia

Primary outcomes

1

Description

Invalidation in patient with fibromyalgia.

Timepoint

Before starting the study, then one month after taking medication.

Method of measurement

Illness invalidation questionnaire.

2

Description

Depression score in Beck depression inventory.

Timepoint

Before starting the study,then one month after taking medication.

Method of measurement

Beck depression questionnaire.

Secondary outcomes

1

Description

severity of disease

Timepoint

Before starting the study, then one month after taking medication.

Method of measurement

FIQR Questionnaire

Intervention groups

1

Description

Intervention group: Group one includes patients diagnosed with fibromyalgia receiving duloxetine with the initial dose of 30 mg daily in form of oral capsule for one month. The dose will be increased up to 60 mg daily after 1 week depending on tolerance. Duloxetine (Cymbalta (Lilly company - USA) is a serotonine and

norepinephrine reuptake inhibitor with formula of C18H19NOS. It can be administered either before or after meals.

Category

Treatment - Drugs

2

Description

Intervention group2: Group two includes patients diagnosed with fibromyalgia receiving Pregabalin capsule orally with the initial dose of 75 mg daily for one month .the dose will be increased up to 150 mg daily after 1week depending on tolerance.. Pregabalin (Lyrica (Pfizer - USA))has the formula of C8H17NO2 and its active metabolite is N-methyl pregabalin.

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Razi hospital clinic

Full name of responsible person

Banafsheh gavidel parsa

Street address

Esteghamat avenue.,razi clinic tower

City

Rasht

Province

Guilan

Postal code

4144895655

Phone

+98 13 3353 0169

Email

Bghavidelparsa@gmail.com

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Rasht University of Medical Sciences

Full name of responsible person

Shadman nemati

Street address

Rasht,Namjoo avenue,shahid siadati street,infrint of 17shahrivar hospital

City

Rasht

Province

Guilan

Postal code

4144895655

Phone

+98 13 3333 6394

Email

Bghavidelparsa@gmail.com

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Rasht University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Rasht University of Medical Sciences

Full name of responsible person

Banafshe Ghavidel parsa

Position

Associate professor

Latest degree

Subspecialist

Other areas of specialty/work

Internal Medicine

Street address

Sardr jangal avenue ,razi hospital

City

Rasht

Province

Guilan

Postal code

4144895655

Phone

+98 13 3353 0169

Email

Bghavidelparsa@gmail.com

Person responsible for scientific inquiries

Contact

Name of organization / entity

Rasht University of Medical Sciences

Full name of responsible person

Banafsheh ghavidel parsa

Position

Medical student

Latest degree

Subspecialist

Other areas of specialty/work

Internal Medicine

Street address

Sardare jangal avenue,Razi hospital

City
Rasht
Province
Guilan
Postal code
4144895655
Phone
+98 13 3353 0169
Email
Bghavidelparsa@gmail.com

Person responsible for updating data

Contact
Name of organization / entity
Rasht University of Medical Sciences
Full name of responsible person
Banafsheh Ghavidelparsa
Position
Associate professor
Latest degree
Subspecialist
Other areas of specialty/work
Medical Education
Street address
Sardare jangal avenue ,razi hospital
City
Rasht
Province
Guilan

Postal code
4144895655
Phone
+98 13 3353 0169
Email
Ashkan96shamami@gmail.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)
Undecided - It is not yet known if there will be a plan to make this available
Study Protocol
Undecided - It is not yet known if there will be a plan to make this available
Statistical Analysis Plan
Undecided - It is not yet known if there will be a plan to make this available
Informed Consent Form
Undecided - It is not yet known if there will be a plan to make this available
Clinical Study Report
Undecided - It is not yet known if there will be a plan to make this available
Analytic Code
Undecided - It is not yet known if there will be a plan to make this available
Data Dictionary
Undecided - It is not yet known if there will be a plan to make this available